Papapit Tuchinda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Papapit Tuchinda has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Kanokvalai Kulthanan
Department of Dermatology Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand
28 shared publications - Leena Chularojanamontri
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
16 shared publications - Chuda Rujitharanawong
Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
6 shared publications Leena Chularojanamontri
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
5 shared publications- Leena Chularojanamontri
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
4 shared publications Puan Suthipinittharm
College of Medicine and Public Health, Ubon Ratchathani University, Ubon Ratchathani, Thailand
4 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Open AccessFactors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- Open Access
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Open AccessThe Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
- Open Access
- 14 May 2024
- Published by Wiley in Experimental Dermatology
- Vol. 33 (5) , e15095
Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17‐year retrospective study
Limited data exist on the factors associated with hospitalization and mortality in Asian inpatients with autoimmune bullous dermatoses (AIBDs). This study aimed to elucidate the risk factors affecting hospitalization and mortality rates in Asian patients with AIBDs. A retrospective analysis of patients with AIBDs treated at Siriraj Hospital during a 17‐year period was performed using the International Classification of Diseases 10th revision codes. The characteristics of inpatients and outpatients were compared, and mortality rates and associated factors were identified. The study included 360 AIBD patients (180 inpatients, 180 outpatients). Inpatients were significantly younger than outpatients. The identified risk factors for hospitalization were malignancy (odds ratio [OR] 2.83, 95% confidence interval [CI] 1.13–8.04; p = 0.034), moderate to severe disease (OR 2.52, 95% CI 1.49–4.34; p < 0.001), systemic corticosteroid use ≥15 mg/day (OR 2.27, 95% CI 1.21–4.41; p = 0.013) and oral cyclophosphamide treatment (OR 9.88, 95% CI 3.82–33.7; p < 0.001). Kaplan–Meier analysis revealed mortality rates of 26%, 36% and 39% for inpatients with pemphigus at 1, 3 and 5 years, respectively. For inpatients with pemphigoid, the corresponding rates were 28%, 38% and 47%. Infections, particularly pneumonia, were the predominant cause of death in both conditions. This study confirmed that both Asian ethnicity and healthcare disparities may be correlated with adverse outcomes in patients with AIBDs. Pemphigus mortality rates were substantially greater in Asian patients than in Caucasian patients. Continuous monitoring of factors contributing to hospitalization and mortality is imperative to improve treatment outcomes.
- 14 May 2024
- Published by Wiley in Experimental Dermatology
- Vol. 33 (5) , e15095
Open AccessHospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17‐year retrospective study
Limited data exist on the factors associated with hospitalization and mortality in Asian inpatients with autoimmune bullous dermatoses (AIBDs). This study aimed to elucidate the risk factors affecting hospitalization and mortality rates in Asian patients with AIBDs. A retrospective analysis of patients with AIBDs treated at Siriraj Hospital during a 17‐year period was performed using the International Classification of Diseases 10th revision codes. The characteristics of inpatients and outpatients were compared, and mortality rates and associated factors were identified. The study included 360 AIBD patients (180 inpatients, 180 outpatients). Inpatients were significantly younger than outpatients. The identified risk factors for hospitalization were malignancy (odds ratio [OR] 2.83, 95% confidence interval [CI] 1.13–8.04; p = 0.034), moderate to severe disease (OR 2.52, 95% CI 1.49–4.34; p < 0.001), systemic corticosteroid use ≥15 mg/day (OR 2.27, 95% CI 1.21–4.41; p = 0.013) and oral cyclophosphamide treatment (OR 9.88, 95% CI 3.82–33.7; p < 0.001). Kaplan–Meier analysis revealed mortality rates of 26%, 36% and 39% for inpatients with pemphigus at 1, 3 and 5 years, respectively. For inpatients with pemphigoid, the corresponding rates were 28%, 38% and 47%. Infections, particularly pneumonia, were the predominant cause of death in both conditions. This study confirmed that both Asian ethnicity and healthcare disparities may be correlated with adverse outcomes in patients with AIBDs. Pemphigus mortality rates were substantially greater in Asian patients than in Caucasian patients. Continuous monitoring of factors contributing to hospitalization and mortality is imperative to improve treatment outcomes.
- Open Access
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 309-314
Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Jirawattanadon P, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):309-314. https://doi.org/10.7774/cevr.2024.13.4.309
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 309-314
Open AccessClinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Jirawattanadon P, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):309-314. https://doi.org/10.7774/cevr.2024.13.4.309
- Open Access
- 29 November 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 7468453
Do Antinuclear Antibodies Influence the Clinical Features of Chronic Spontaneous Urticaria?: A Retrospective Cohort Study
Background. Antinuclear antibody (ANA) is often used as a screening test for autoimmune comorbidities in patients with chronic spontaneous urticaria (CSU). However, the relationship of ANA status and the clinical course of the disease have not been fully described. Objectives. To compare clinical features of CSU patients who are positive and negative for ANA. Methods. This was a retrospective cohort study that enrolled CSU patients attending the Urticaria Clinic at Siriraj Hospital from 2013 to 2019. Demographics, clinical characteristics, laboratory investigations, and treatments were collected until July 2021. All patients were investigated for ANA. Clinical feature data was compared between CSU patients with positive ANA and negative ANA groups using the 2‐sample t‐test and the Mann–Whitney U test for quantitative variables. The chi‐squared test or Fisher’s exact test was conducted to explore the association of qualitative variables. Disease relapse and remission were analysed via Kaplan‐Meier survival analysis. Results. Of 323 CSU patients, 31% had positive ANA. There were no significant differences in disease severity or impairment in quality of life. Patients with a positive ANA test had significantly lower prevalence of allergic rhinitis (p = .048) and significantly higher level of erythrocyte sedimentation rate (p = 0.007). Kaplan‐Meier survival analysis showed that 2% of ANA positive CSU patients achieved remission status after one year and 28% did so after five years. There was no statistically significant difference in time to remission and time to relapse between ANA‐positive and negative groups. Conclusion. Positive ANA in CSU patients could not indicate the differences in main disease characteristics from the ANA‐negative CSU patients. Investigation for ANA may be useful in CSU patients who are suspected of having autoimmune diseases.
- 29 November 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 7468453
Open AccessDo Antinuclear Antibodies Influence the Clinical Features of Chronic Spontaneous Urticaria?: A Retrospective Cohort Study
Background. Antinuclear antibody (ANA) is often used as a screening test for autoimmune comorbidities in patients with chronic spontaneous urticaria (CSU). However, the relationship of ANA status and the clinical course of the disease have not been fully described. Objectives. To compare clinical features of CSU patients who are positive and negative for ANA. Methods. This was a retrospective cohort study that enrolled CSU patients attending the Urticaria Clinic at Siriraj Hospital from 2013 to 2019. Demographics, clinical characteristics, laboratory investigations, and treatments were collected until July 2021. All patients were investigated for ANA. Clinical feature data was compared between CSU patients with positive ANA and negative ANA groups using the 2‐sample t‐test and the Mann–Whitney U test for quantitative variables. The chi‐squared test or Fisher’s exact test was conducted to explore the association of qualitative variables. Disease relapse and remission were analysed via Kaplan‐Meier survival analysis. Results. Of 323 CSU patients, 31% had positive ANA. There were no significant differences in disease severity or impairment in quality of life. Patients with a positive ANA test had significantly lower prevalence of allergic rhinitis (p = .048) and significantly higher level of erythrocyte sedimentation rate (p = 0.007). Kaplan‐Meier survival analysis showed that 2% of ANA positive CSU patients achieved remission status after one year and 28% did so after five years. There was no statistically significant difference in time to remission and time to relapse between ANA‐positive and negative groups. Conclusion. Positive ANA in CSU patients could not indicate the differences in main disease characteristics from the ANA‐negative CSU patients. Investigation for ANA may be useful in CSU patients who are suspected of having autoimmune diseases.
- Open Access
- 27 October 2022
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 12 (4) , e39
Natural history and clinical course of patients with dermographism in a tropical country: a questionnaire-based survey
Background: Dermographism is the most common form of chronic inducible urticaria. However, the natural history and clinical course of patients with dermographism in tropical countries has not fully been described. Objective: To examine clinical features, natural history and clinical course of dermographism in Thai patients according to their experiences. Methods: A cross-sectional, internet-based survey was conducted in 2021. All study respondents completed a 45-item questionnaire that was circulated on social media regarding dermographism. Results: Among the 2,456 respondents who reported dermographism, 1,900 had symptomatic dermographism (SD), while 556 had simple dermographism (SimD). Of the respondents who reported SD and SimD, the female to male ratio was 2.2:1 and 2.4:1, respectively. The median age of the first episode of SD and SimD was 16 and 15 years, respectively. Older age, greater body weight, cardiovascular diseases, allergic conjunctivitis, atopic dermatitis, changes in temperature, and family history of dermographism were all factors linked to an increased probability of SD. Half of the respondents with SD reported moderate itch severity. Moreover, about half of SD and almost all of SimD respondents let the wheal resolve on its own. Second generation H1-antihistamines were most commonly prescribed while over-the-counter medicines were taken by both SD and SimD respondents. Conclusion: This survey highlights several aspects of dermographism in Thai patients which can be useful for healthcare providers. SD is troublesome and affects the quality of life of many patients, leading some to seek medication themselves.
- 27 October 2022
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 12 (4) , e39
Open AccessNatural history and clinical course of patients with dermographism in a tropical country: a questionnaire-based survey
Background: Dermographism is the most common form of chronic inducible urticaria. However, the natural history and clinical course of patients with dermographism in tropical countries has not fully been described. Objective: To examine clinical features, natural history and clinical course of dermographism in Thai patients according to their experiences. Methods: A cross-sectional, internet-based survey was conducted in 2021. All study respondents completed a 45-item questionnaire that was circulated on social media regarding dermographism. Results: Among the 2,456 respondents who reported dermographism, 1,900 had symptomatic dermographism (SD), while 556 had simple dermographism (SimD). Of the respondents who reported SD and SimD, the female to male ratio was 2.2:1 and 2.4:1, respectively. The median age of the first episode of SD and SimD was 16 and 15 years, respectively. Older age, greater body weight, cardiovascular diseases, allergic conjunctivitis, atopic dermatitis, changes in temperature, and family history of dermographism were all factors linked to an increased probability of SD. Half of the respondents with SD reported moderate itch severity. Moreover, about half of SD and almost all of SimD respondents let the wheal resolve on its own. Second generation H1-antihistamines were most commonly prescribed while over-the-counter medicines were taken by both SD and SimD respondents. Conclusion: This survey highlights several aspects of dermographism in Thai patients which can be useful for healthcare providers. SD is troublesome and affects the quality of life of many patients, leading some to seek medication themselves.
- 1 July 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (11) , E419-E421
New‐onset and exacerbated skin diseases after COVID‐19 infection: A systematic review
- 1 July 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (11) , E419-E421
New‐onset and exacerbated skin diseases after COVID‐19 infection: A systematic review
- 5 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , E251-E252
Rituximab‐induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review
- 5 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , E251-E252
Rituximab‐induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review
- Open Access
- 25 February 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-6
Development and Evaluation of an In-House ELISA to Detect Anti-FcεR1α IgG Autoantibodies in Chronic Spontaneous Urticaria Patients
Background. Association between chronic spontaneous urticaria (CSU) and autoimmunity has been well documented. Autologous serum skin testing could support the autoimmune etiology of CSU, whereas it is difficult to interpret and could not be performed on antihistamine omitted patients. It was found that immunoglobulin G (IgG) autoantibodies (autoAbs) against high-affinity IgE receptor (FcεR1) were suggested as a potential trigger in the pathogenesis of CSU. Although many ELISA protocols have been developed to detect these autoAbs, they lacked validation or a reliable cut-off point. We, therefore, aimed to develop a validated ELISA with a reliable cut-off point to quantitate IgG anti-FcεR1α autoAbs for CSU. Methods. We developed an in-house ELISA to quantitate IgG anti-FcεR1α autoAbs. Sera from 233 CSU patients and 25 healthy people were used to test with ELISA. The cut-off point was obtained from the results subjected to analyze with receiver operating characteristic (ROC) analysis. ELISA was validated with 116 CSU patients and 150 healthy donors. Results. ELISA revealed that healthy people had a basal level of IgG anti-FcεR1α autoAbs, whereas their levels were significantly lower than autoAbs levels in CSU patients. ROC analysis of ELISA determined the cut-off point at 936.7ng/ml. Our ELISA was validated and provided excellent sensitivity and specificity at 98.28 and 92.67, respectively. Conclusion. Our ELISA could detect significant levels of IgG anti-FcεR1α autoAbs in CSU, supporting that these autoAbs were associated with CSU etiology. Our validated ELISA with the reliable cut-off point provided excellent accuracy at 95.11 (98.28 sensitivity and 92.67 specificity). Our ELISA could be an alternative test benefit for the patient who is unable to omit antihistamine treatment.
- 25 February 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-6
Open AccessDevelopment and Evaluation of an In-House ELISA to Detect Anti-FcεR1α IgG Autoantibodies in Chronic Spontaneous Urticaria Patients
Background. Association between chronic spontaneous urticaria (CSU) and autoimmunity has been well documented. Autologous serum skin testing could support the autoimmune etiology of CSU, whereas it is difficult to interpret and could not be performed on antihistamine omitted patients. It was found that immunoglobulin G (IgG) autoantibodies (autoAbs) against high-affinity IgE receptor (FcεR1) were suggested as a potential trigger in the pathogenesis of CSU. Although many ELISA protocols have been developed to detect these autoAbs, they lacked validation or a reliable cut-off point. We, therefore, aimed to develop a validated ELISA with a reliable cut-off point to quantitate IgG anti-FcεR1α autoAbs for CSU. Methods. We developed an in-house ELISA to quantitate IgG anti-FcεR1α autoAbs. Sera from 233 CSU patients and 25 healthy people were used to test with ELISA. The cut-off point was obtained from the results subjected to analyze with receiver operating characteristic (ROC) analysis. ELISA was validated with 116 CSU patients and 150 healthy donors. Results. ELISA revealed that healthy people had a basal level of IgG anti-FcεR1α autoAbs, whereas their levels were significantly lower than autoAbs levels in CSU patients. ROC analysis of ELISA determined the cut-off point at 936.7ng/ml. Our ELISA was validated and provided excellent sensitivity and specificity at 98.28 and 92.67, respectively. Conclusion. Our ELISA could detect significant levels of IgG anti-FcεR1α autoAbs in CSU, supporting that these autoAbs were associated with CSU etiology. Our validated ELISA with the reliable cut-off point provided excellent accuracy at 95.11 (98.28 sensitivity and 92.67 specificity). Our ELISA could be an alternative test benefit for the patient who is unable to omit antihistamine treatment.
- 23 August 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E532-E538
Adult female acne: Clinical characteristics and factors significantly associated with polycystic ovary syndrome
Background Adult female acne (AFA) may be different from adolescent acne, and may be a sign of polycystic ovary syndrome (PCOS). The objective of the study was to investigate the clinical characteristics of AFA, and the factors significantly associated with PCOS in AFA. Methods AFA patients aged 25 years or older were enrolled. History taking and dermatologic examinations were performed by dermatologists. PCOS was diagnosed by gynaecologists. Perimenopausal acne (aged 45 years or older) and the Dermatology Life Quality Index (DLQI) were also evaluated. Results Among 208 patients, mean age was 31.8 ± 7.1 years and 47.1%, 26.9%, and 26% had persistent, late-onset, and recurrent acne, respectively. The common aggravating factors included pre-menstruation (72.6%) and stress (53.8%). Recurrent acne was significantly aggravated by cosmetic products. Higher body mass index (BMI) was positively correlated with acne severity. Acne lesions were predominately located on both cheeks (87.0%) and at the perioral area (81.7%). PCOS was identified in 48.1%. Younger age (≥25 to <33 years), premenstrual flare, and irregular menstruation, but not hirsutism or androgenetic alopecia, were associated with PCOS in univariate and multivariate analysis. Perimenopausal acne was identified in 6.7%. The total mean DLQI score was 8.0 ± 5.4 (range from 0 to 23). Conclusions Persistent acne with moderate severity was common in AFA patients and higher BMI was associated with acne severity. PCOS should be screened in AFA patients with younger age, premenstrual flare, and irregular menstruation.
- 23 August 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E532-E538
Adult female acne: Clinical characteristics and factors significantly associated with polycystic ovary syndrome
Background Adult female acne (AFA) may be different from adolescent acne, and may be a sign of polycystic ovary syndrome (PCOS). The objective of the study was to investigate the clinical characteristics of AFA, and the factors significantly associated with PCOS in AFA. Methods AFA patients aged 25 years or older were enrolled. History taking and dermatologic examinations were performed by dermatologists. PCOS was diagnosed by gynaecologists. Perimenopausal acne (aged 45 years or older) and the Dermatology Life Quality Index (DLQI) were also evaluated. Results Among 208 patients, mean age was 31.8 ± 7.1 years and 47.1%, 26.9%, and 26% had persistent, late-onset, and recurrent acne, respectively. The common aggravating factors included pre-menstruation (72.6%) and stress (53.8%). Recurrent acne was significantly aggravated by cosmetic products. Higher body mass index (BMI) was positively correlated with acne severity. Acne lesions were predominately located on both cheeks (87.0%) and at the perioral area (81.7%). PCOS was identified in 48.1%. Younger age (≥25 to <33 years), premenstrual flare, and irregular menstruation, but not hirsutism or androgenetic alopecia, were associated with PCOS in univariate and multivariate analysis. Perimenopausal acne was identified in 6.7%. The total mean DLQI score was 8.0 ± 5.4 (range from 0 to 23). Conclusions Persistent acne with moderate severity was common in AFA patients and higher BMI was associated with acne severity. PCOS should be screened in AFA patients with younger age, premenstrual flare, and irregular menstruation.